New CKM guideline urges team-based care, yet UH data show major therapy gaps; CINEMA model boosts outcomes amid cost, trust, and handoff hurdles.
|Articles|January 1, 1999
Supplements and Featured Publications
- Clinical and Therapeutic Advances in the Treatment of Sexual Dysfunction: A Paradigm for Managed Ca
- Volume 5
- Issue 1 Suppl
CME Quiz
Advertisement
Articles in this issue
over 27 years ago
Selected Abstractsover 27 years ago
Bibliographyover 27 years ago
Participating Facultyover 27 years ago
Introductionover 27 years ago
An Overview of Erectile Dysfunctionover 27 years ago
Health Economics and Sexual Dysfunctionover 27 years ago
Managed Care and Sexual Dysfunctionover 27 years ago
Cardiovascular Risk Factors and Erectile Dysfunctionover 27 years ago
The Psychosocial Context of Sexual DysfunctionAdvertisement
Related to this article
Obesity care surges with GLP-1 demand, but fragmented ownership, prior authorizations, and coverage rules stall treatment—pharmacists step in.
Roundtables reveal HFpEF/HFmrEF care lags despite rising cases; learn new SGLT2/MRA strategies, screening, and scalable team pathways.
Simple operational changes are proving more effective at closing gaps in cardiovascular-kidney-metabolic (CKM) syndrome care than education campaigns alone, according to panelists at at Population Health Roundtable
Panelists at AJMC roundtables in Philadelphia, Boston, Washington, DC, and Chicago traced why atopic dermatitis stays undertreated despite new therapies.
Eye care access for underserved patients with diabetes is limited and poorly understood. We identified barriers and innovative solutions to improve overall care and establish evidence-based practices.
Patient understanding should be treated as a measurable equity outcome, not an assumed byproduct of care.
Advertisement
Advertisement
Trending on AJMC
1
FDA Expands Finerenone Approval to CKD Associated With Type 1 Diabetes
2
Delayed Dupilumab Raises Asthma Costs 32%: Nicola Hanania, MD
3
A Patient-Centered Reconstruction of 340B in Oncology: Transparency, Equity, and Site-of-Care Accountability
4
Twice-Yearly CD19 Therapy Targets MG Root Cause: Richard Nowak, MD, MS
5